Cellectis S.A. (CLLS)
- Previous Close
2.6400 - Open
2.4600 - Bid --
- Ask 4.7500 x 50000
- Day's Range
2.4600 - 2.6497 - 52 Week Range
0.9630 - 3.7740 - Volume
45,642 - Avg. Volume
37,838 - Market Cap (intraday)
190.655M - Beta (5Y Monthly) 3.13
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.43
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
www.cellectis.comRecent News: CLLS
Performance Overview: CLLS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLLS
Valuation Measures
Market Cap
188.26M
Enterprise Value
204.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.37
Price/Book (mrq)
2.50
Enterprise Value/Revenue
12.42
Enterprise Value/EBITDA
-3.67
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.78%
Return on Equity (ttm)
-71.28%
Revenue (ttm)
24.52M
Net Income Avi to Common (ttm)
-71.89M
Diluted EPS (ttm)
-1.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
67.36M
Total Debt/Equity (mrq)
109.72%
Levered Free Cash Flow (ttm)
-48.23M